{
    "nct_id": "NCT06265727",
    "official_title": "A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors",
    "inclusion_criteria": "* Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active of uncontrolled CNS metastases\n* History of solid tumors other than the diseases under study\n* History of and/or current cardiovascular events or conditions in the previous 6 months\n* Pre-existing >/= Grade 2 neuropathy\n* Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy\n* Active ocular disease at baseline\n* Chronic severe liver disease or live cirrhosis\n* Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study\n* Other significant cormorbidities.",
    "miscellaneous_criteria": ""
}